Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 150 results for "sarabjit kour nangra"

Infosys' topline a positive surprise; revenue growth commendab...

In a chat with ET Now, Sarabjit Kour Nangra, Angel Broking, talks about Infosys' latest numbers. Excerpts: ET Now: Prima facie, Infosys' numbers look okay. What is your take? Sarabjit Kour Nangra: Infosys' topline has positively surprised. 4.5% ... Economic Times, 1 week ago

1 images for "sarabjit kour nangra"

Business Standard, 6 months ago

Tech Mahindra and many small caps have indicated trend of lower revenue for Q1: Sarabjit Kour Nangra

In an interview with ET Now, Sarabjit Kour Nangra from Angel Broking expresses her outlook on lower revenue trends indicated by Tech Mahindra and other IT organizations. ET Now: Tech Mahindra has come out with its report, they are saying that the ...
 Economic Times1 month ago

Most of large-cap pharma stocks are pretty balanced in terms of valuation: Sarabjit Kour Nangra, Angel Broking

I believe the overall stock reaction today is in view of the same. Secondly, Sun Pharma management has refrained from giving any guidance for the current year. In an interview with ET Now, Sarabjit Kour Nangra, VP - Research, Angel Broking, Pharma, shares his ...
 Economic Times1 month ago Ranbaxy effect playing on Sun Pharma's margins: Pros  Money Control2 months ago

IT firms feel the pinch as clients review tech spend

With global clients reviewing their investments in traditional technology upgradation and, instead, investing in newer technologies like cloud, analytics and social media, competition among information technology (IT) outsourcing services providers ...
 Smart Investor1 day ago IT firms face pricing pressure as clients review spending  Smart Investor1 day ago

Tech Mahindra shows profit of `676 crore in first quarter

Chennai IT major Tech Mahindra reported a net profit of Rs 676.07 crore for the quarter ended June 30, 2015, compared to Rs 630.72 for the corresponding quarter the previous year. However, the company’s operating profit was down from Rs 779.20 crore in Q1 ...
 The Financial Chronicle2 days ago Tech Mahindra shows profit of Rs 676 cr in first quarter  Financial Chronicle2 days ago Wipro Q1 net profit up 4% at Rs2,187 cr  The Financial Chronicle6 days ago Tech Mahindra Q4 PAT at Rs 472 crore  The Financial Chronicle2 months ago

Tech Mahindra Q1 net up 43% on other income, $ rev in line

Software solutions provider Tech Mahindra surpassed street expectations on bottomline & operational front Monday while revenue met estimates. Consolidated net profit in first quarter climbed 43 percent sequentially to Rs 676 crore, supported by ...
 Moneycontrol.com2 days ago Tech Mahindra gains 2% on tie up with BPM software vendor  Moneycontrol.com3 weeks ago TechM projects tepid Q1 revenues, stock dives 7%  The Financial Chronicle1 month ago

Teva-Allergan deal will not impact Indian pharma, says experts

Indian pharmaceutical companies and industry experts do not see a downside for Indian drug makers following drug maker Teva's $40 billion dollar acquisition of Allergan.Jerusalem-based Teva was the world's largest generic drug maker by sales in ...
 Smart Investor2 days ago

EU ban on GVK-tested drugs from August 21

The European Commission, the executive body of the European Union (EU), has formally put into effect the suspension of 700-odd drugs that underwent bio-equivalence studies at a facility of Hyderabad-based GVK Bio Sciences. The suspension had been ...
 Business Standard India3 days ago EU-wide ban on suspended drugs from August 21  Smart Investor4 days ago

Under the weather

India's pharma sector has been presenting mixed growth trends. On the one hand, growing demand is presenting an opportunity, while on the other, many factors are impacting the non-homogeneous sector. Some recent key developments included fixing of price caps ...
 The Financial Chronicle3 days ago

Lupin to get first US plant with GAVIS buy

Acquisition of US-based co for $880 million is biggest by an Indian drug maker; gives Lupin 66 abbreviated new drug application filings over 65 products under development In biggest acquisition by an Indian drugmaker overseas, Lupin on Thursday ...
 DNA India6 days ago Lupin gets first US plant with GAVIS buy [DNA : Daily News & Analysis (India)]  Pharmacy Choice4 days ago Lupin gets US FDA approval for anti-diabetes drug  Business Standard India1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - sarabjit kour nangra
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less